Tapentadol — research review 1

...So, let's talk about Tapentadol, a pain medication that acts on opioid receptors and also inhibits norepinephrine reuptake. It’s used for moderate to severe pain, and it raises some interesting questions about long-term health and aging.

Absolutely. While managing chronic pain is crucial—and, importantly, untreated pain itself can accelerate biological aging, as seen in painful diabetic neuropathy associated with accelerated epigenetic aging and telomere shortening (GeroScience 2025)—we also need to look at the long-term impact of the treatments.

Right. And here's where it gets complex. Research indicates that chronic opioid use, including medications like Tapentadol, is associated with a higher risk of all-cause mortality compared to short-term use. A study in Public Health (2024) found a hazard ratio of 1.37 for all-cause mortality with chronic opioid use.

And that risk can be compounded. For instance, combining opioids with gabapentinoids, a common practice, significantly increases the risk of CNS depression and mortality. One study in Front Pharmacol (2022) reported an odds ratio of 2.76 for this combination.

So, it’s not just about the pain relief itself, but also about the potential for serious long-term harms like falls, sedation, dependence, and cognitive issues, particularly in older adults.

Exactly. The key is balance. For many, Tapentadol provides necessary pain relief when appropriately prescribed and supervised. But for others, especially considering the links to all-cause mortality and CNS depression, it underscores the need for careful consideration of risks versus benefits, particularly when looking at biological aging and overall longevity. What's still unknown is the precise mechanism linking long-term opioid use to biological aging markers beyond all-cause mortality.